Tracy L. Bahl: Educating Providers on Biosimilars

Tracy L. Bahl, president and chief executive officer of OneOncology, discusses the education his organization has provided to physicians on biosimilars.


So each of our clinical leaders, including Drs Vacirca, Patton, Brooks, and of course Schwartzberg, have been engaging their practices from a communication, education, training, and orientation standpoint, to really equip their clinicians to understand the clinical efficacy and availability for the patients they're serving, both initiating new therapy as [well as] those that might well be in the midst of therapy today. It's really a full-force effort on our part, to bring that kind of understanding across the clinical team.